Protagonist Therapeutics
PTGX
138 hedge funds and large institutions have $2.15B invested in Protagonist Therapeutics in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
88% more capital invested
Capital invested by funds: $1.15B → $2.15B (+$1B)
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
67% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 36
9% more funds holding
Funds holding: 127 → 138 (+11)
1.29% more ownership
Funds ownership: 101.2% → 102.48% (+1.3%)
53% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $2.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$27.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$26.3M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$24.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$18M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$32.4M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.84M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.52M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.79M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$6.78M |
PTGX Hedge Fund Activity: Q2 2021 in Review
138 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2021, worth a combined $2.15B — up 88% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PTGX positions and 15 closed out — a net gain of 11 holders — while 60 added to existing stakes and 36 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $27.9M. The largest seller was Baker Bros. Advisors, cutting an estimated $32.4M.
- 138 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2021, up from 127 in Q1 2021.
- Funds reported $2.15B of Protagonist Therapeutics stock for Q2 2021, up 88% quarter-over-quarter.
- 26 funds opened new Protagonist Therapeutics positions in Q2 2021 and 15 closed out, a net change of +11 holders.
- The largest Protagonist Therapeutics buyer in Q2 2021 was Victory Capital Management, an estimated $27.9M added.
- The largest Protagonist Therapeutics seller in Q2 2021 was Baker Bros. Advisors, an estimated $32.4M sold.
Based on aggregated 13F filings for Q2 2021.